Saving...

Saving...

wiki.Alumni.NET - Your Location Information Resource

Asia/India/Karnataka/Bangalore - Urban/AstraZeneca India/

From wiki.Alumni.NET

Jump to: navigation, search

Coordinates: 13°03′03″N 77°35′48″E 13.0508318, 77.5967145

AstraZeneca India

  • Address: Off Bellary Road, Hebbal, Bangalore - Urban, Karnataka, India 560 024
  • Phone:
    • +91-80-6774 8000
    • +91-80-334 0449 (fax)
  • Website: [1]
  • Job Listing
  • Overview

Astra AB was founded in 1913 by 400 doctors and apothecaries in Södertälje, Sweden. In 1994 the company formed a joint venture with Merck to market Losec, an ulcer-treatment drug. [1]

In 1993 ICI demerged its pharmaceuticals businesses and its agrochemicals and specialties businesses, to form Zeneca Group plc. [1]

In 1999 Astra AB and Zeneca Group plc merged to form AstraZeneca plc. [1]

In 2005 the company announced an arrangement with Astex for the discovery, development and commercialisation of novel small molecule inhibitors of protein kinase B for use as anti-cancer agents. In the same year it announced a collaboration with Avanir for research and licensing in the area of reverse cholesterol transport (RCT) enhancing compounds for the treatment of cardiovascular disease. It also announced an alliance with Schering AG for research and licensing in the area of selective glucocorticoid receptor agonists (SEGRAs). It also announced that it had become a Diamond Member of the Pennsylvania Bio commerce organization. [1]

In 2006, following a collaborative relationship begun in 2004, AstraZeneca acquired Cambridge Antibody Technology. [1]

Also in 2006 it formed an alliance with Abbott Laboratories in relation to Crestor and TriCor, commencing that year and extending to at least 2009. [1]

In 2007 it reported that it had entered into an alliance with Bristol-Myers Squibb to form a global collaboration to develop and commercialise two investigational drugs (saxagliptin and dapagliflozin) beginning from 2007. [1]

Also in 2007 AstraZeneca acquired American company MedImmune for about $15.2 billion. AstraZeneca consolidated its biologics portfolio in MedImmune and Cambridge Antibody Technology which was rebranded to create a dedicated biologics division known as 'MedImmune'. [1]

  • View Comments and Reviews
  • Add a New Comment or Review

Visitors

  • Directions
    • Car
    • Public Transportation

Gallery



Personal tools